To the best of our knowledge, this work is the first to provide clinical evidence of resistance to crizotinib and sensitivity to alectinib in NSCLC patients harboring acquired <i>ALK</i> C1156F mutation. The gene discussed is ALK; the disease is non-small cell lung carcinoma.